Development and characterization of a fully human antibody targeting SCF/c-kit signaling.
Antibody
Cancer
Crystal structure
SCF
c-kit
Journal
International journal of biological macromolecules
ISSN: 1879-0003
Titre abrégé: Int J Biol Macromol
Pays: Netherlands
ID NLM: 7909578
Informations de publication
Date de publication:
15 Sep 2020
15 Sep 2020
Historique:
received:
13
02
2020
revised:
06
05
2020
accepted:
06
05
2020
pubmed:
22
5
2020
medline:
10
3
2021
entrez:
22
5
2020
Statut:
ppublish
Résumé
CD117/c-kit, a tyrosine kinase receptor, plays a critical role in hematopoiesis, pigmentation, and fertility. The overexpression and activation of c-kit are thought to promote tumor growth and have been reported in various cancers, including leukemia, glioblastoma and mastocytosis. To disrupt the SCF/c-kit signaling axis in cancer, we generated a c-kit antagonist human antibody (NN2101) that binds to domain 2/3 of c-kit. This completely blocked the SCF-mediated phosphorylation of c-kit and inhibited TF-1 cell proliferation, erythroleukemia. In addition, the examination of binding affinity using surface plasmon resonance (SPR) assay showed that NN2101 can bind to c-kit of monkeys (K
Identifiants
pubmed: 32437800
pii: S0141-8130(20)33190-1
doi: 10.1016/j.ijbiomac.2020.05.045
pii:
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antineoplastic Agents, Immunological
0
Epitopes
0
Proto-Oncogene Proteins c-kit
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
66-78Informations de copyright
Copyright © 2020. Published by Elsevier B.V.
Déclaration de conflit d'intérêts
Declaration of competing interest None.